spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Cytel to Acquire SDS Life Science and SDS MedteQ to Enhance and Expand Thought-Leadership in Strategic Therapeutic Development

Cytel





Pictured (from left to right): Albert Kim, Chief Medical Officer at Cytel, Joshua Schultz, CEO at Cytel. Anna Törner, Founder of SDS Life Sciences and Maria Lundberg, CEO at SDS Life Science.

Waltham, MA, October 13, 2022 – Cytel Inc., provider of quantitative insights and health data analytics to leaders in life sciences, has entered into an agreement to acquire SDS Life Science AB and SDS MedteQ AB. The move will add new global talent to Cytel’s Strategic Consulting group and bring additional expertise and capabilities for the strategic development of drugs and medical devices. As a result, sponsors will have easier access to a larger, geographically expanded pool of consulting expertise to help them get new therapies to patients faster. The acquisition furthers Cytel’s global expansion and continues the company’s journey of building a diverse, multi-disciplinary, and strategic thought partner for sponsors developing new therapeutics across the biopharma and medical technology ecosystem.

As drug development becomes more complex and competitive, pharmaceutical companies need faster and better ways to bring their therapies to market. For 35 years, Cytel’s Strategic Consulting group has pioneered advanced biostatistics, decision science, and real-world evidence capabilities that enable sponsors to optimize new therapeutic development. SDS Life Science has an equally rich heritage in biostatistics and shares Cytel's commitment to the innovative design of clinical trials and development programs, using advanced statistical and computational approaches to improve trials for patients and sponsors.

“Cytel and SDS have a tightly aligned philosophy of excellence, a harmonious knowledge base, and proven reputations as industry leaders and strategic business partners for life sciences leadership teams,” says Cytel CEO Joshua Schultz. “By fusing our like-minded knowledge pools, we are building critical new capabilities and enhancing our offering across every dimension important for efficiently developing novel therapies including pre-clinical, real world evidence, regulatory affairs, drug development, clinical project management, biostatics and medtech.

With SDS Life Science and SDS MedteQ supporting more than 100 biomedical sponsors in Scandinavia, in addition to several multinational pharmaceutical companies, the acquisition continues Cytel’s rapid growth into new global markets.

"We are now a team that can draw on a wealth of truly global talent," says Cytel’s Chief Medical Officer Dr Albert Kim, "This acquisition adds to the already diverse intellectual community we have at Cytel and strengthens the innovative culture we value. For our customers, this means more of the innovation and thought leadership that shapes impactful development programs, now more deeply connected and accessible across new geographies, and all delivered with our established dedication to customer collaboration.”

"We are looking forward to joining forces with Cytel and adding the capabilities of their tools to our service delivery. We’ll continue to help sponsor teams efficiently overcome their toughest challenges, and with our combined science and data-based approaches and entrepreneurial spirit, we will become greater than just the sum of our parts" states Maria Lundberg, CEO, SDS Life Science.

Anna Törner, Founder of SDS Life Sciences adds “As part of the Cytel Strategic Consulting group, we will be offering services at a higher strategic level, particularly with regards to trial design, RWE and data science. This will ultimately benefit the innovative Nordic life science environment and patients".

The transaction is subject to customary closing conditions and is expected to close this quarter.

To learn more about the work of Cytel Strategic Consulting, please visit: cytel.com/solutions#innovative_trial_design

For more information about SDS Life Science and SDS MedteQ, please visit sdslifescience.com or sdsmedteq.com
phone +1 (617) 661-2011
email support@cytel.com
web https://www.cytel.com/
email 1050 Winter St Suite 2700 Waltham, MA 02451 USA
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Blood Tests May Prevent Relapse in Breast Cancer Patients

The Royal Marsden NHS Foundation Trust is leading an international research collaboration to offer blood tests that can identify risk of relapse in breast cancer patients. The trial will assess whether personalised blood tests can show which patients will relapse, years before it’s shown on a scan - treatment can then be altered to try and prevent relapse from happening. There are currently no effective tests to establish which patients are at risk of relapse after previous treatment for breast cancer.
More info >>


White Papers

A Rules Based Approach to Labelling and Artwork Management

Kallik

Many organisations today are experiencing unprecedented demands from regulatory authorities and consumers alike for product labelling to be made clearer and more informative. Forthcoming regulations (including the new EU MDR regulations coming into force May 2020) also require that labelling content to be published electronically in addition to print. As companies seek to continuously differentiate themselves in established markets as well as gain entry into new territories, the increase in both volume and complexity of product and market variations will have a direct impact on labelling.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement